These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22470917)

  • 1. [Accidental discoveries, different mechanisms of action. Active agents against Mycobacterium tuberculosis in clinical application].
    Weeken D; Schlitzer M
    Pharm Unserer Zeit; 2012 Jan; 41(1):35-47. PubMed ID: 22470917
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of Mycobacterium tuberculosis topoisomerase I by m-AMSA, a eukaryotic type II topoisomerase poison.
    Godbole AA; Ahmed W; Bhat RS; Bradley EK; Ekins S; Nagaraja V
    Biochem Biophys Res Commun; 2014 Apr; 446(4):916-20. PubMed ID: 24642256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reappraising the use of β-lactams to treat tuberculosis.
    Kurz SG; Bonomo RA
    Expert Rev Anti Infect Ther; 2012 Sep; 10(9):999-1006. PubMed ID: 23106275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Old and new anti-mycobacterial drugs. Fatty acid synthesis as a target].
    Topf CM; Schiebel J; Kisker C; Holzgrabe U
    Pharm Unserer Zeit; 2012 Jan; 41(1):64-70. PubMed ID: 22470920
    [No Abstract]   [Full Text] [Related]  

  • 5. Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs.
    Blanco D; Perez-Herran E; Cacho M; Ballell L; Castro J; González Del Río R; Lavandera JL; Remuiñán MJ; Richards C; Rullas J; Vázquez-Muñiz MJ; Woldu E; Zapatero-González MC; Angulo-Barturen I; Mendoza A; Barros D
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1868-75. PubMed ID: 25583730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting DNA Gyrase to Combat Mycobacterium tuberculosis: An Update.
    Das S; Garg T; Srinivas N; Dasgupta A; Chopra S
    Curr Top Med Chem; 2019; 19(8):579-593. PubMed ID: 30834837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure of Type-I Mycobacterium tuberculosis fatty acid synthase at 3.3 Å resolution.
    Elad N; Baron S; Peleg Y; Albeck S; Grunwald J; Raviv G; Shakked Z; Zimhony O; Diskin R
    Nat Commun; 2018 Sep; 9(1):3886. PubMed ID: 30250274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Could Killing Bacterial Subpopulations Hit Tuberculosis out of the Park?
    Baranowski C; Rubin EJ
    J Med Chem; 2016 Jul; 59(13):6025-6. PubMed ID: 27322073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Welcome to 'Tuberculosis drug discovery and development'.
    D'Oca G
    Future Med Chem; 2010 Aug; 2(8):1241-2. PubMed ID: 21426014
    [No Abstract]   [Full Text] [Related]  

  • 10. Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
    Chaudhari K; Surana S; Jain P; Patel HM
    Eur J Med Chem; 2016 Nov; 124():160-185. PubMed ID: 27569197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prospects for design of novel antituberculosis drugs].
    Nikitin AV
    Antibiot Khimioter; 2006; 51(9-10):56-60. PubMed ID: 18030793
    [No Abstract]   [Full Text] [Related]  

  • 12. Mycobacterium tuberculosis cytochrome P450 enzymes: a cohort of novel TB drug targets.
    Hudson SA; McLean KJ; Munro AW; Abell C
    Biochem Soc Trans; 2012 Jun; 40(3):573-9. PubMed ID: 22616869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
    Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S95-S101. PubMed ID: 27742640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current challenges in drug discovery for tuberculosis.
    Kumar A; Chettiar S; Parish T
    Expert Opin Drug Discov; 2017 Jan; 12(1):1-4. PubMed ID: 27797593
    [No Abstract]   [Full Text] [Related]  

  • 15. β-Lactams against Tuberculosis--New Trick for an Old Dog?
    Diacon AH; van der Merwe L; Barnard M; von Groote-Bidlingmaier F; Lange C; García-Basteiro AL; Sevene E; Ballell L; Barros-Aguirre D
    N Engl J Med; 2016 Jul; 375(4):393-4. PubMed ID: 27433841
    [No Abstract]   [Full Text] [Related]  

  • 16. Have we realized the full potential of β-lactams for treating drug-resistant TB?
    Story-Roller E; Lamichhane G
    IUBMB Life; 2018 Sep; 70(9):881-888. PubMed ID: 29934998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicine. New TB drug promises shorter, simpler treatment.
    Cohen J
    Science; 2004 Dec; 306(5703):1872. PubMed ID: 15591168
    [No Abstract]   [Full Text] [Related]  

  • 18. Discovery of novel acetohydroxyacid synthase inhibitors as active agents against Mycobacterium tuberculosis by virtual screening and bioassay.
    Wang D; Zhu X; Cui C; Dong M; Jiang H; Li Z; Liu Z; Zhu W; Wang JG
    J Chem Inf Model; 2013 Feb; 53(2):343-53. PubMed ID: 23316686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future for early-stage tuberculosis drug discovery.
    Zuniga ES; Early J; Parish T
    Future Microbiol; 2015; 10(2):217-29. PubMed ID: 25689534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the research of heterocyclic compounds as antitubercular agents.
    Yan M; Ma S
    ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.